In a subgroup of patients from this study (N = 79), SSc patients with high baseline CXCL4 levels had accelerated progression of ILD as measured by a decline in the diffusing capacity for carbon monoxide (DLCO) [16]. The gene discussed is PF4; the disease is systemic sclerosis.